Relapse after allogeneic hematopoietic stem cell transplant in patients with chronic myeloid leukemia: tyrosine kinase inhibitors, donor lymphocyte infusions or both?
a Division of Hematology, Department of Internal Medicine , Cerrahpasa Faculty of Medicine, Istanbul University , Istanbul , Turkey.
Ahmet Emre
AE
Eskazan
a Division of Hematology, Department of Internal Medicine , Cerrahpasa Faculty of Medicine, Istanbul University , Istanbul , Turkey.
Isil
I
Erdogan
a Division of Hematology, Department of Internal Medicine , Cerrahpasa Faculty of Medicine, Istanbul University , Istanbul , Turkey.
Selin
S
Berk
a Division of Hematology, Department of Internal Medicine , Cerrahpasa Faculty of Medicine, Istanbul University , Istanbul , Turkey.
Fevzi Firat
FF
Yalniz
a Division of Hematology, Department of Internal Medicine , Cerrahpasa Faculty of Medicine, Istanbul University , Istanbul , Turkey.
Tugrul
T
Elverdi
a Division of Hematology, Department of Internal Medicine , Cerrahpasa Faculty of Medicine, Istanbul University , Istanbul , Turkey.
Ayse
A
Salihoglu
a Division of Hematology, Department of Internal Medicine , Cerrahpasa Faculty of Medicine, Istanbul University , Istanbul , Turkey.
Teoman
T
Soysal
D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology* / Q000628:therapy*; D017710:Lymphocyte Transfusion; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D012008:Recurrence; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D047428:Protein Kinase Inhibitors